Add a fibrate to a statin? by Lounsbery, Jody L. et al.
582 THE JOURNAL OF FAMILY PRACTICE  |   OCTOBER 2010  |   VOL 59, NO 10
Priority Updates from the Research Literature 
from the Family Physicians Inquiries Network
Jody Lounsbery, 
PharmD, BCPS; 
Shailendra Prasad, MD, 
MBBS, MPH; 
Kate Rowland, MD 
North Memorial 
Family Medicine Residency, 
University of Minnesota, 
Minneapolis 
(Drs. Lounsbery and 
Prasad); Department of 
Family Medicine, University 
of Chicago (Dr. Rowland) 
 P U R L s  E D I T O R
John Hickner, MD, MSc
Cleveland Clinic
Add a fi brate to a statin? 
For most patients with diabetes and dyslipidemia, adding 
a fi brate does not improve cardiovascular outcomes.
PRACTICE CHANGER
Do not routinely add a fi brate to a statin for 
patients with type 2 diabetes who are at high 
risk for cardiovascular events.1 
STRENGTH OF RECOMMENDATION
B: Based on a good-quality randomized 
controlled trial. 
Th e ACCORD Study Group. Eff ects of combination lipid therapy in type 
2 diabetes mellitus. N Engl J Med. 2010;362:1563-1574.
ILLUSTRATIVE CASE
A 60-year-old man with cardiovascular disease 
and diabetes comes to your clinic for a routine 
check of his dyslipidemia, for which he is on 
statin therapy. His fasting lipid panel shows 
a low-density lipoprotein (LDL) of 70 mg/dL, 
triglycerides of 200 mg/dL, and a high-density 
lipoprotein (HDL) of 30 mg/dL. Should you rec-
ommend adding fenofi brate?
Patients with type 2 diabetes are at increased risk for cardiovascular events. National Cholesterol Educa-
tion Program Adult Treatment Panel (NCEP 
ATP) III guidelines recommend treatment 
of dyslipidemia for all patients with high risk 
of cardiovascular events to an LDL goal of 
<100 mg/dL (optional <70 mg/dL), HDL goal 
of >40 mg/dL, and triglyceride goal of 
<150 mg/dL. Th ese recommendations include 
the use of combination therapy with a statin 
and fenofi brate for patients who have elevated 
triglycerides and low HDL cholesterol despite 
being on statin therapy alone.2 
Survival beneﬁ t of combo therapy 
remains unproven 
We know that fi brate therapy alone in patients 
with type 2 diabetes reduces major cardiovas-
cular events.3,4 We also know that adding a fi -
brate to statin therapy can help patients reach 
their HDL and triglyceride targets. However, 
the survival benefi t of the fi brate-statin combi-
nation over that of a statin alone has not been 
proven. In addition, there have been concerns 
about the increased risk of adverse eff ects with 
the combination. In fact, the overall benefi ts 
(and risks) of combining fi brates and statins 
for patients with diabetes and dyslipidemia 
were not addressed in a large randomized trial 
until the study we report on here. 
STUDY SUMMARY
Statin + ﬁ brate = minimal beneﬁ t
for most patients 
Th e Action to Control Cardiovascular Risk in 
Diabetes (ACCORD) study is among the larg-
est trials conducted in adults with type 2 dia-
betes at high risk of cardiovascular events.5 
Th e study examined 3 approaches to lower-
ing the risk of major cardiovascular events: 
intensive lowering of blood sugar levels com-
pared with standard blood sugar treatment; 
intensive lowering of blood pressure (BP) 
compared with standard BP treatment; and 
treatment of lipids with 2 drugs—a fi brate 
plus a statin—compared with a statin alone. 
Th is summary focuses on the lipid arm of the 
ACCORD study.1 
All patients in the study had type 2 
diabetes and a hemoglobin A1c ≥7.5%. Th e 
study included patients ages 40 to 79 years with 
clinical evidence of cardiovascular disease and 
patients ages 55 to 79 years with either subclin-
ical cardiovascular disease or ≥2 cardiovascu-
lar risk factors in addition to diabetes. 
583JFPONLINE.COM VOL 59, NO 10  |  OCTOBER 2010  |  THE JOURNAL OF FAMILY PRACTICE
Th e lipid arm enrolled patients who had 
an LDL cholesterol of 60 to 180 mg/dL, an 
HDL cholesterol <55 mg/dL for women and 
blacks and <50 mg/dL for all other groups, 
and a triglyceride level <750 mg/dL for those 
not receiving lipid therapy and <400 mg/dL 
for those on lipid therapy. Enrollees (N=5518) 
were started on open-label simvastatin 20 mg, 
titrated up as needed to reach the LDL goal, 
then randomized to receive either fenofi brate 
or placebo 1 month later. Th e mean duration 
of follow-up was 4.7 years.
❚ The primary outcome was the fi rst oc-
currence of a major cardiovascular event—
nonfatal myocardial infarction (MI), nonfatal 
stroke, or death from a cardiovascular cause. 
Th e annual rate of the primary outcome was 
2.2% (n=291) in the fenofi brate-statin group 
and 2.4% (n=310) in the placebo group, a non-
signifi cant diff erence (P=.32). 
Th e results were reported by sex. Th e pri-
mary outcome rate for men during the 4.7-year 
follow-up was 11.2% in the fenofi brate-statin 
group vs 13.3% in the placebo group; for wom-
en, the outcome rates were 9.1% in the treat-
ment group and 6.6% in the placebo group 
(P =.01). Th ese rates suggest a small benefi t for 
men, and harm for women. 
❚ Subgroup analysis showed additional 
beneﬁ t from fenofi brate in patients with a 
combination of a high baseline triglyceride 
level (≥204 mg/dL) and very low baseline HDL 
cholesterol (≤34 mg/dL), representing about 
16% of the study participants. Th e primary 
outcome rate for patients in this subgroup 
was 12.4% in the fenofi brate-statin group and 
17.3% in the placebo group (P=.057); num-
ber needed to treat (NNT)=20 patients for 4.7 
years to prevent 1 major cardiovascular event.
❚ Harm was similar in both groups. A 
small number of patients had elevations of al-
anine aminotransferase of >3 times the upper 
limit of normal (1.9% in the fenofi brate-statin 
group and 1.5% in the statin group). Th e study 
drug was discontinued in 66 patients (2.4%) in 
the fenofi brate-statin group (and the placebo 
was discontinued in 30 patients [1.1%] in the 
statin group). Th e fenofi brate or statin dose 
was reduced in 440 patients (15.9%) in the 
fenofi brate-statin group and in 194 patients 
(7%) in the statin group due to a decrease in 
estimated glomerular fi ltration rate. Th ere 
was no signifi cant diff erence in the incidence 
of hemodialysis and end-stage renal disease 
(75 patients in the fenofi brate-statin group vs 
77 patients in the statin group). 
WHAT’S NEW
We have evidence that combo therapy
doesn’t further reduce risk 
Th is study examined a previously unad-
dressed question, the role of combination 
fi brate-statin therapy in high-risk patients 
with type 2 diabetes. Th e fi ndings do not sup-
port the routine use of combination therapy 
compared with a statin alone for most patients 
with diabetes. Overall, combination therapy 
with simvastatin and fenofi brate did not lower 
the risk of MI, stroke, or death from cardiovas-
cular disease more than simvastatin alone. 
Th is trial showed that women with diabe-
tes and hyperlipidemia should not be treated 
with both a statin and a fi brate. Men appeared 
to have a very small benefi t from combina-
tion therapy (NNT=50). Patients with a base-
line HDL ≤34 mg/dL and baseline triglyceride 
≥204 mg/dL appeared to benefi t from the 
combination, but this group constituted only 
16% of the patients in this trial and the diff er-
ence had borderline statistical signifi cance. 
Nonetheless, it may be reasonable to treat 
such patients with combination therapy until 
a defi nitive study is done.
CAVEATS
Statin dose did not match 
standard practice
Th is study used a low dose of statin. Th e aver-
age daily simvastatin dose was 22.3 mg in the 
fenofi brate-statin group and 22.4 mg in the pla-
cebo group. Th is constitutes low-dose therapy 
compared with doses routinely used in practice 
(ie, 40 or 80 mg). A higher dose of simvastatin 
may have negated any outcome diff erences.
CHALLENGES TO IMPLEMENTATION
This “practice changer” 
conﬂ icts with NCEP guidelines
Th e current NCEP ATP III guidelines recom-
mend combination fi brate-statin therapy for 
all patients when statin therapy alone is not 
Do you prescribe 
fi brates for patients 
with type 2 diabetes 
who fail to reach 
lipid goals on statin 
therapy alone?
■  Yes, I routinely pre-
scribe combination 
therapy
■  Occasionally; it 
depends on the 
patient 
■  Rarely or never
■ Other _____________
Go to jfponline.com
and take our instant poll 
INSTANT 
POLL
QUESTION
adequate to achieve lipid goals. Th is is a ma-
jor challenge to our recommendation against 
using this combination for most patients with 
diabetes. Some physicians may choose to fol-
low the ATP III guidelines rather than the new 
evidence because they feel more confi dent 
adhering to national guidelines. 
Clinical inertia is another challenge, as 
clinicians may be hesitant to stop therapy in 
patients already on a fi brate-statin combina-
tion. Finally, specialists may continue to use 
fi brate-statin combinations in all patients with 
diabetes who do not achieve lipid goals on a 
statin, and family physicians may hesitate to 
contradict their recommendations.               JFP
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